Clinical
Resistance profiling at the point of care
Screening patients on arrival in ICU and high-risk wards, so isolation and therapy decisions are made in the same shift as the swab. Carbapenemases are the validated entry assay.
Fluiscope
Resistance leaves
Resistance leaves
a signal.
We read it in
a few minutes.
Antimicrobial resistance — whichever mechanism, whichever host — is diagnosed 24 to 72 hours after the sample is taken, in a central lab, by trained staff. Fluiscope puts the answer at the point of need: hospitals, waste water treatment plants, agri-food plants and in the environment.
Our versatile technological platform detects antimicrobial resistance across varying constraints and environmental conditions.
The diagnostic gap
Waiting for the lab is itself a driver of resistance.
Culture and antibiotic susceptibility testing take one to three days. In the meantime, patients receive broad-spectrum antibiotics, contaminated effluent is already downstream, food batches are contaminated. The delay isn't an inconvenience — it enables resistance to spread and compound.
Fluiscope reduces total analysis time through breakthrough detection technologies
Culture + AST — central lab24–72 h
Trained staffLab infrastructureSample transport
Fluiscope — point of need15 min – 6 h
15 min for the test itselfUp to 6 h with a short enrichment stepNo trained operatorDigital result
What that changes
Isolation decisions during the admission window, not after it. Proper treatment from day zero. Surveillance data that arrives while it can still inform an action — in a hospital, a slaughterhouse, or a wastewater plant.
One Health positioning
Resistance moves between humans, animals and water. A detection platform should too.
Most diagnostics companies pick one vertical and build a dedicated instrument for it. Fluiscope's electrochemical core and lateral-flow chemistry are the same in all three. That holds across sectors: one R&D investment, three core components.
Veterinary & agri-food
Screening before the chain, not after
Herd-level resistance screening and surface hygiene swabs along the food chain, where sending samples to a lab is rarely proportionate to the decision being made.
Environment
Resistance surveillance in water
On-site AMR and microbial monitoring at treatment plants and in surface water — the surveillance layer the revised Urban Wastewater Treatment Directive turns from optional to mandatory.
The platform
Two sensing pillars, countless possibilities.
Lateral flow and electrochemistry are not competing options, they are two instruments in the same hand. Either one can stand alone: a strip where speed and simplicity decide, an electrode where you need a quantitative, traceable measurement. Put them together and each covers the other's blind spot. Which arrangement applies is a question about your use case — the matrix, the decision, the constraints on site — not about the technology.
Electrochemical sensing — BYG
Disposable printed carbon electrodes read the electrical signature of an enzymatic reaction. Quantitative, digital, and small enough to sit next to the bench it serves. Four channels run in parallel, controls included.
- Quantitative, digital, operator-independent
- Scope: bacteria, physico-chemical contaminants, chemical parameters
Lateral flow assays — LFA
Capillary migration on a paper strip with gold-nanoparticle-labelled antibodies. Result in minutes, no instrument, no trained operator, unit costs that survive routine screening. The format that goes where a laboratory cannot.
- Rapid, visual, no instrument required
- Scope: bacteria, viruses, physico-chemical, contaminants
Hybrid platform
The two pillars can be combined in more than one way, and the use case decides which. Physically integrated in a single cartridge where the sample allows it. Run side by side when two independent signals on the same sample are what buys confidence. Run in sequence — strip first as a triage, electrode second to confirm and quantify — when the decision is a rapid one and the cost of a false call is high.
- Modular, connected and reliable detection platform
Example: electrochemical readout of AMR for multiple strains
Use case 01 · clinical AMR
Carbapenem resistance: where the platform is already validated.
Carbapenems are a last-resort antibiotic. When an Enterobacterales isolate produces a carbapenemase — KPC, NDM, VIM, OXA-48, IMP — the clinician is near the end of the therapeutic line, and reported mortality for carbapenem-resistant infections runs between 20 and 40%. This is the use case where a few hours of diagnostic delay changes an outcome, which is why we validated here first.
Culture sets the clock. At least six hours of growth before any test can run — so everything after it had better be fast.
Immunochromatographic strips
Fast, but blind to the unexpected
Quick and simple, widely used as a first-line screen — but they recognise known enzyme families only. An uncovered variant or atypical expression can pass unseen, and they say nothing about actual enzymatic activity.
Rapid phenotypic tests
Functional, but hard to read
These measure activity rather than a predefined genetic panel, which is their great advantage. But colour reading is subjective, sensitive to inoculum and operating conditions, and ambiguous at low activity levels.
Reference methods
Complete, but too slow to act on
Full AST needs 24 to 48 hours. PCR runs €40–50 per test on dedicated infrastructure and detects genes whether or not they are expressed.
The gap, and what we add
A pre-antibiogram, not another test to reconcile.
No universal phenotypic test returns robust information in under fifteen minutes, and no single device couples a rapid screen to a digitalised functional confirmation. So laboratories run several tests in cascade — complex interpretation, late decision, no native digital trace of how the conclusion was reached.
Our contribution is a short sequential protocol combining our two sensing pillars: a rapid lateral flow screen, then a BYG electrochemical read that confirms and characterises the result. One digital verdict, delivered inside the window where it can still change a decision.
We are not proposing to replace the reference methods. We are shortening the interval in which a clinician has nothing to act on — what the literature calls diagnostic stewardship: changing how tests are ordered, run and reported so that treatment improves, resistance pressure falls, and laboratory resources go where they matter (Fabre et al., 2023).
Sequenced roadmap
Each phase builds on development previously made.
Turning one validated test into a One Health detection platform. We prove the kit where the clinical stakes are highest, license it where partners already own the channel, then extend the same reader and the same chemistry across sectors — each phase inheriting the work of the one before it rather than starting over.
Phase 1
Today
Clinical validation
Carbapenem resistance detection kit, clinically validated at CHU UCL Namur — Mont-Godinne. The reference case that establishes the platform.
Phase 2
2027 – 2028
Licensing and extension
The carbapenem kit licensed to industrial partners, with coverage extended to the detection of other antibiotic resistances on the same platform.
Phase 3
2028 onwards
One Health extension
Extension to other contaminants and other sectors, across the three One Health domains — water and environment, the veterinary and agri-food chain, and the clinic.
Valorization
An R&D laboratory for sensing solutions.
Fluiscope is built to do the part that is hard to copy — sensor science, assay development, integration: under contract for partners, through licences on what we develop in-house, and through small production runs that let end users validate a test before anyone commits to industrial scale.
01 / Contract R&D
Sensor development for partners
Custom electrochemical and LFA sensor development on a CRO basis — from a partner's target to a working prototype in weeks to months. Paid development, the partner keeps the application.
02 / Licensing
IP portfolio, licences & royalties
Technologies we develop in-house, protected with UCLouvain and clinical partners, then licensed out: upfront fees, development milestones and per-unit royalties from diagnostics manufacturers. Revenue that scales without our headcount.
03 / Mini-series
Research-use-only production
Small production runs of research-use-only tests, so end users can validate performance on their own samples and in their own conditions before industrialisation is on the table.
Peer-reviewed science
Published first, then validated in hospitals.
Both sensing pillars have been through peer review, and the electrochemical assay through a multicentre clinical evaluation. The performance figures quoted on this page come from these papers — not from our own bench.
Journal of Clinical Microbiology · 2016
Evaluation of the BYG Carba Test, a new electrochemical assay for rapid laboratory detection of carbapenemase-producing Enterobacteriaceae
Read the paper →
Scientific Reports · 2017
Multicentre evaluation of the BYG Carba v2.0 test, a simplified electrochemical assay for the rapid laboratory detection of carbapenemase-producing Enterobacteriaceae
Read the paper →
ACS Applied Bio Materials · 2024
Rapid and specific detection of Bacillus cereus using phage protein-based lateral flow assays
Read the paper →
Eco-design
A faster test should not mean a heavier one.
Testing at the point of need removes a trip to the central lab, and with it the transport and the infrastructure behind it. But the disposable that takes its place carries a footprint of its own — and almost nobody measures it. A review led by our co-founder Grégoire Le Brun found only thirteen life-cycle assessments published across the whole biosensor field.
So we measure. That review proposes the Environmental Cost of Performance, a metric that ties analytical sensitivity to environmental impact so a design choice can be judged on both at once. We apply it to our own kits — where the packaging, not the chemistry, usually turns out to be the problem.
30–300 gCO₂-eq per lateral flow test, cradle to grave
0.5–3 kgCO₂-eq per test on instrumented platforms
~20,000 tPlastic waste from lateral flow tests each year
13Life-cycle assessments published on biosensors
Team
Twenty years of sensor research, run as a company.
Grégoire Le Brun
Co-CEO · Technology
PhD UCLouvain, MBA Solvay. ~10 years of lateral flow assay development across academic and industrial settings.
LinkedIn
Sami Yunus
Scientific Director
PhD in electronics. +15 years in electrochemical sensing; first author of the BYG Carba clinical evaluation.
LinkedIn
Nils Préat
Co-CEO · Business
PhD in biosciences, MBA Solvay, former McKinsey. Leads commercial strategy, licensing and partnerships.
LinkedInWork with us
Bring us a target. We build the sensor around it.
Whether you need resistance data faster than your current lab loop allows, a sensor for a contaminant nobody sells a test for, or a platform to license into your own product line — the conversation starts the same way: what are you trying to detect, and what decision depends on it.
- Pilot sites: hospitals, water utilities, food producers, veterinary practices
- Licensing: diagnostics manufacturers looking for a validated AMR platform
- Co-development: Horizon Europe, LIFE, or direct R&D contracts
Partnership contact
Contact us- Fluiscope SRL
- Rue de la Station 19
1300 Wavre — Belgium - VAT
- BE 1031.611.034
- info@fluiscope.com
Proudly supported by
Watch and read
The technologies in action.
Short films of the kits being run, and the coverage our work has had in the Belgian press.
Fluiscope
Resistance leaves
Resistance leaves
a signal.
We read it in
a few minutes.
Antimicrobial resistance — whichever mechanism, whichever host — is diagnosed 24 to 72 hours after the sample is taken, in a central lab, by trained staff. Fluiscope puts the answer at the point of need: hospitals, waste water treatment plants, agri-food plants and in the environment.
Our versatile technological platform detects antimicrobial resistance across varying constraints and environmental conditions.
The diagnostic gap
Waiting for the lab is itself a driver of resistance.
Culture and antibiotic susceptibility testing take one to three days. In the meantime, patients receive broad-spectrum antibiotics, contaminated effluent is already downstream, food batches are contaminated. The delay isn't an inconvenience — it enables resistance to spread and compound.
Fluiscope reduces total analysis time through breakthrough detection technologies
Culture + AST — central lab24–72 h
Trained staffLab infrastructureSample transport
Fluiscope — point of need15 min – 6 h
15 min for the test itselfUp to 6 h with a short enrichment stepNo trained operatorDigital result
What that changes
Isolation decisions during the admission window, not after it. Proper treatment from day zero. Surveillance data that arrives while it can still inform an action — in a hospital, a slaughterhouse, or a wastewater plant.
One Health positioning
Resistance moves between humans, animals and water. A detection platform should too.
Most diagnostics companies pick one vertical and build a dedicated instrument for it. Fluiscope's electrochemical core and lateral-flow chemistry are the same in all three. That holds across sectors: one R&D investment, three core components.
Clinical
Resistance profiling at the point of care
Screening patients on arrival in ICU and high-risk wards, so isolation and therapy decisions are made in the same shift as the swab. Carbapenemases are the validated entry assay.
Veterinary & agri-food
Screening before the chain, not after
Herd-level resistance screening and surface hygiene swabs along the food chain, where sending samples to a lab is rarely proportionate to the decision being made.
Environment
Resistance surveillance in water
On-site AMR and microbial monitoring at treatment plants and in surface water — the surveillance layer the revised Urban Wastewater Treatment Directive turns from optional to mandatory.
The platform
Two sensing pillars, countless possibilities.
Lateral flow and electrochemistry are not competing options, they are two instruments in the same hand. Either one can stand alone: a strip where speed and simplicity decide, an electrode where you need a quantitative, traceable measurement. Put them together and each covers the other's blind spot. Which arrangement applies is a question about your use case — the matrix, the decision, the constraints on site — not about the technology.
Electrochemical sensing — BYG
Disposable printed carbon electrodes read the electrical signature of an enzymatic reaction. Quantitative, digital, and small enough to sit next to the bench it serves. Four channels run in parallel, controls included.
- Quantitative, digital, operator-independent
- Scope: bacteria, physico-chemical contaminants, chemical parameters
Lateral flow assays — LFA
Capillary migration on a paper strip with gold-nanoparticle-labelled antibodies. Result in minutes, no instrument, no trained operator, unit costs that survive routine screening. The format that goes where a laboratory cannot.
- Rapid, visual, no instrument required
- Scope: bacteria, viruses, physico-chemical, contaminants
Hybrid platform
The two pillars can be combined in more than one way, and the use case decides which. Physically integrated in a single cartridge where the sample allows it. Run side by side when two independent signals on the same sample are what buys confidence. Run in sequence — strip first as a triage, electrode second to confirm and quantify — when the decision is a rapid one and the cost of a false call is high.
- Modular, connected and reliable detection platform
Example: electrochemical readout of AMR for multiple strains
Use case 01 · clinical AMR
Carbapenem resistance: where the platform is already validated.
Carbapenems are a last-resort antibiotic. When an Enterobacterales isolate produces a carbapenemase — KPC, NDM, VIM, OXA-48, IMP — the clinician is near the end of the therapeutic line, and reported mortality for carbapenem-resistant infections runs between 20 and 40%. This is the use case where a few hours of diagnostic delay changes an outcome, which is why we validated here first.
Culture sets the clock. At least six hours of growth before any test can run — so everything after it had better be fast.
Immunochromatographic strips
Fast, but blind to the unexpected
Quick and simple, widely used as a first-line screen — but they recognise known enzyme families only. An uncovered variant or atypical expression can pass unseen, and they say nothing about actual enzymatic activity.
Rapid phenotypic tests
Functional, but hard to read
These measure activity rather than a predefined genetic panel, which is their great advantage. But colour reading is subjective, sensitive to inoculum and operating conditions, and ambiguous at low activity levels.
Reference methods
Complete, but too slow to act on
Full AST needs 24 to 48 hours. PCR runs €40–50 per test on dedicated infrastructure and detects genes whether or not they are expressed.
The gap, and what we add
A pre-antibiogram, not another test to reconcile.
No universal phenotypic test returns robust information in under fifteen minutes, and no single device couples a rapid screen to a digitalised functional confirmation. So laboratories run several tests in cascade — complex interpretation, late decision, no native digital trace of how the conclusion was reached.
Our contribution is a short sequential protocol combining our two sensing pillars: a rapid lateral flow screen, then a BYG electrochemical read that confirms and characterises the result. One digital verdict, delivered inside the window where it can still change a decision.
We are not proposing to replace the reference methods. We are shortening the interval in which a clinician has nothing to act on — what the literature calls diagnostic stewardship: changing how tests are ordered, run and reported so that treatment improves, resistance pressure falls, and laboratory resources go where they matter (Fabre et al., 2023).
Sequenced roadmap
Each phase builds on development previously made.
Turning one validated test into a One Health detection platform. We prove the kit where the clinical stakes are highest, license it where partners already own the channel, then extend the same reader and the same chemistry across sectors — each phase inheriting the work of the one before it rather than starting over.
Phase 1
Today
Clinical validation
Carbapenem resistance detection kit, clinically validated at CHU UCL Namur — Mont-Godinne. The reference case that establishes the platform.
Phase 2
2027 – 2028
Licensing and extension
The carbapenem kit licensed to industrial partners, with coverage extended to the detection of other antibiotic resistances on the same platform.
Phase 3
2028 onwards
One Health extension
Extension to other contaminants and other sectors, across the three One Health domains — water and environment, the veterinary and agri-food chain, and the clinic.
Valorization
An R&D laboratory for sensing solutions.
Fluiscope is built to do the part that is hard to copy — sensor science, assay development, integration: under contract for partners, through licences on what we develop in-house, and through small production runs that let end users validate a test before anyone commits to industrial scale.
01 / Contract R&D
Sensor development for partners
Custom electrochemical and LFA sensor development on a CRO basis — from a partner's target to a working prototype in weeks to months. Paid development, the partner keeps the application.
02 / Licensing
IP portfolio, licences & royalties
Technologies we develop in-house, protected with UCLouvain and clinical partners, then licensed out: upfront fees, development milestones and per-unit royalties from diagnostics manufacturers. Revenue that scales without our headcount.
03 / Mini-series
Research-use-only production
Small production runs of research-use-only tests, so end users can validate performance on their own samples and in their own conditions before industrialisation is on the table.
Peer-reviewed science
Published first, then validated in hospitals.
Both sensing pillars have been through peer review, and the electrochemical assay through a multicentre clinical evaluation. The performance figures quoted on this page come from these papers — not from our own bench.
Journal of Clinical Microbiology · 2016
Evaluation of the BYG Carba Test, a new electrochemical assay for rapid laboratory detection of carbapenemase-producing Enterobacteriaceae
Read the paper →
Scientific Reports · 2017
Multicentre evaluation of the BYG Carba v2.0 test, a simplified electrochemical assay for the rapid laboratory detection of carbapenemase-producing Enterobacteriaceae
Read the paper →
ACS Applied Bio Materials · 2024
Rapid and specific detection of Bacillus cereus using phage protein-based lateral flow assays
Read the paper →
Eco-design
A faster test should not mean a heavier one.
Testing at the point of need removes a trip to the central lab, and with it the transport and the infrastructure behind it. But the disposable that takes its place carries a footprint of its own — and almost nobody measures it. A review led by our co-founder Grégoire Le Brun found only thirteen life-cycle assessments published across the whole biosensor field.
So we measure. That review proposes the Environmental Cost of Performance, a metric that ties analytical sensitivity to environmental impact so a design choice can be judged on both at once. We apply it to our own kits — where the packaging, not the chemistry, usually turns out to be the problem.
30–300 gCO₂-eq per lateral flow test, cradle to grave
0.5–3 kgCO₂-eq per test on instrumented platforms
~20,000 tPlastic waste from lateral flow tests each year
13Life-cycle assessments published on biosensors
Team
Twenty years of sensor research, run as a company.
Grégoire Le Brun
Co-CEO · Technology
PhD UCLouvain, MBA Solvay. ~10 years of lateral flow assay development across academic and industrial settings.
LinkedIn
Sami Yunus
Scientific Director
PhD in electronics. +15 years in electrochemical sensing; first author of the BYG Carba clinical evaluation.
LinkedIn
Nils Préat
Co-CEO · Business
PhD in biosciences, MBA Solvay, former McKinsey. Leads commercial strategy, licensing and partnerships.
LinkedInWork with us
Bring us a target. We build the sensor around it.
Whether you need resistance data faster than your current lab loop allows, a sensor for a contaminant nobody sells a test for, or a platform to license into your own product line — the conversation starts the same way: what are you trying to detect, and what decision depends on it.
- Pilot sites: hospitals, water utilities, food producers, veterinary practices
- Licensing: diagnostics manufacturers looking for a validated AMR platform
- Co-development: Horizon Europe, LIFE, or direct R&D contracts
Partnership contact
Contact us- Fluiscope SRL
- Rue de la Station 19
1300 Wavre — Belgium - VAT
- BE 1031.611.034
- info@fluiscope.com
Proudly supported by
Watch and read
The technologies in action.
Short films of the kits being run, and the coverage our work has had in the Belgian press.